Figure 1 (Renflexis 01)
Renflexis
Product Images NDC 0006-4305
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Renflexis (NDC 0006-4305). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Merck Sharp & Dohme Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 2 (Renflexis 02)
Figure 3 (Renflexis 03)
This text appears to describe two different medical interventions: "Placebo" and "Infliximab 5 mg/kg". Beyond that, there is not enough context to determine what conditions the interventions might be used for or what their respective effects might be.*
Figure 4 (Renflexis 04)
Principal Display Panel (100 mg Vial Carton)
This is a description of RENFLEXIS™ medication for injection. It is available in 100mg/vial dosage. The medication must be refrigerated at a temperature of 2-8°C and has a shelf life of up to 6 months. The product must be reconstituted and diluted before intravenous infusion, and must be infused over at least 2 hours with an inline filter. The instructions for preparing the medication are provided on the package. It is manufactured by Samsung Bioepis and distributed by Merck Sharp & Dohme. It is meant for intravenous infusion only and must be administered by a healthcare professional. There is a packaging insert with medication guide that should be given to each patient. The medication contains Infliximab-abda. No usage information is available if the text contains it.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
